EX-10.13
from 10-K
1 page
1 March 2022 Mark Watson Inhibitor Therapeutics Wmwatson@wmwatson.com Dear Mark Second Loan Amendment Mayne Pharma Ventures Pty Ltd (Mayne Pharma) Is Offering to Amend the Loan Outlined in Our Letter Signed 12 December 2020, as Amended on 10 January 2022 (Loan) to Provide a Loan to Inhibitor Therapeutics, Inc. (INTI), as Set Out Below. Line Amount: The Facility Limit Is Increased by Usd50,000 to Usd331,000. Availability: The Usd50,000 Increase in the Facility Limit Is Available for Draw Down From 1 April 2022 Until 31 May 2022. the Parties Acknowledge That the Following Funds Have Already Been Drawn Down Under the Facility: • Usd55,000 Paid on 22 December 2020 • Usd26,000 Paid on 1 Feb 2021 • Usd75,000 Paid on 19 March 2021, • Usd75,000 Paid on 11 June 2021, and • Usd50,000 Paid on 1 February 2022. Maturity: 31 December 2022
12/34/56
EX-10.1
from 8-K
1 page
10 January 2022 Mark Watson Inhibitor Therapeutics Dear Mark Loan Amendment Mayne Pharma Ventures Pty Ltd (Mayne Pharma) Is Offering to Amend the Loan Outlined in Our Letter Signed 12 December 2020 (Loan) to Provide a Loan to Inhibitor Therapeutics, Inc. (INTI), as Set Out Below. Line Amount: The Facility Limit Is Increased by Usd50,000 to Usd281,000. Availability: The Usd50,000 Increase in the Facility Limit Is Available for Draw Down From 1 February 2022 Until 31 March 2022. the Parties Acknowledge That the Following Funds Have Already Been Drawn Down Under the Facility: • Usd55,000 Paid on 22 December 2020 • Usd26,000 Paid on 1 Feb 2021 • Usd75,000 Paid on 19 March 2021, and • Usd75,000 Paid on 11 June 2021. Maturity: 31 December 2022
12/34/56
